Stephen M. Forthuber
Known title: See RemarksCIK: 0001325578
Associated companies
Transaction History
| RDNT | ▼ Sell | Open Market | 24,214 | $1.4M | 6/15/2026 | View on chart |
| RDNT | ▼ Sell | Open Market | 19,853 | $1.2M | 6/15/2026 | View on chart |
| RDNT | ▲ Buy | Grant | 22,045 | $0 | 3/3/2026 | View on chart |
| RDNT | ▼ Sell | Open Market | 31,790 | $2.5M | 12/5/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 11,598 | $917K | 12/5/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 1,700 | $136K | 12/5/2025 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 39,127 | $238K | 12/3/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 18,820 | $1.1M | 5/16/2025 | View on chart |
| RDNT | ▲ Buy | Grant | 27,681 | $0 | 1/8/2025 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 1,380 | — | 1/4/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 40,000 | $2.5M | 6/12/2024 | View on chart |
| RDNT | ▲ Buy | Grant | 17,434 | $0 | 3/1/2024 | View on chart |
| RDNT | ▲ Buy | Grant | 18,036 | $0 | 1/9/2024 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 1,380 | — | 1/4/2024 | View on chart |
| RDNT | ▼ Sell | Open Market | 10,000 | $230K | 3/16/2023 | View on chart |
| RDNT | ▲ Buy | Grant | 17,435 | $0 | 1/3/2023 | View on chart |
| RDNT | ▲ Buy | Grant | 20,804 | $0 | 1/4/2022 | View on chart |
| RDNT | ▲ Buy | Grant | 2,755 | $0 | 9/21/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
RadNet Q2 Earnings and AI Study News
RadNet received positive marks for its second-quarter testing and diagnostics services earnings. Additionally, a new study suggests DeepHealth AI could help avoid nearly one in five prostate biopsies. These developments provide context for the stock's current position within its 52-week range.
RadNet Q2 Earnings and AI Study News. RadNet received positive marks for its second-quarter testing and diagnostics services earnings. Additionally, a new study suggests DeepHealth AI could help avoid nearly one in five prostate biopsies. These developments provide context for the stock's current position within its 52-week range.